Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

If you are a CI/PI of an upcoming clinical trial, with accompanying laboratory studies, you may want to consider using the new state-of-the-art GCP Therapy Acceleration Laboratory (TAL) based at the Medical Research Council Weatherall Institute of Molecular Medicine (MRC WIMM) for the laboratory studies.

The TAL analyses human samples from national and international Phase I to Phase III trials of novel targeted therapies that maximise patient impact, transform understanding of disease biology and dissect mechanisms of action of therapies and mechanisms of response. It is open to all PIs in Oxford and offers a wide selection of Next Generation Sequencing genetic and deep phenotyping assays on cells and tissues. The TAL works closely with the WIMM Single Cell and Imaging facilities and supports long-term bio-banking of nucleic acids and viable cells.

The TAL has applied to the United Kingdom Accreditation Service (UKAS) to be accredited to ISO/IEC 17025:2017 in 2024.

The laboratory works with CIs/PIs to add value to a clinical trial, offering assays that allow:

  • Patient selection at the start of a trial
  • Patient stratification into different therapy arms during the trial
  • Validation of secondary endpoints for more rapid trials and exploratory endpoints.

Careful analysis can also provide mechanistic data on how therapies work in patients, providing confidence to regulators.